中偉股份(300919.SZ):現在印尼鎳資源佈局的項目合計有19.5萬金屬噸
格隆匯5月10日丨中偉股份(300919.SZ)於2024年5月9日召開業績説明會,就“中偉目前在印尼佈局的鎳資源冶煉產能有多少萬噸?有多少火法冶煉,有佈局濕法冶煉的產能嗎?目前鎳資源的自供率能達到多少?”,公司回覆稱,公司現在印尼鎳資源佈局的項目合計有19.5萬金屬噸,以上均為火法冶煉項目,現已建成滿產的為德邦、翡翠灣項目,合計5.5萬噸,其餘項目已開始同步建設,建設完成後將有效提高公司關鍵原料的自供比例,降低原料市場價格波動帶來的衝擊風險,並提高公司產品在國際市場的競爭力;公司現在印尼的佈局暫時只有火法,但公司已經組建濕法研發和工程團隊,未來不排除佈局濕法項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.